Project Grant R44AI142905

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...

The National Institutes of Health (NIH) Office of the Director awarded a $300,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to Sanford Research, a non-profit biomedical research organization, for the project "ENGINEERING HUMAN T REGULATORY CELLS WITH CHIMERIC ANTIGEN RECEPTOR TARGETING NTPDASE3 ON THE SURFACE OF B CELLS FOR TYPE 1 DIABETES CONTROL". The project aims to create and validate a novel, antigen-specific cellular therapy for type 1 diabetes by...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $210,867 to Drexel University to conduct research on developing tolerogenic dendritic cells (TolDCs) as a cell-based therapy to induce immune tolerance in kidney transplant recipients. The key innovation is the use of "push/pull particle" TolDCs that contain microparticles loaded with a synergistic...

This $306,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports preclinical studies to evaluate the efficacy of Mink Therapeutics' cellular immunotherapy product, Agent-797, in reducing graft-versus-host disease (GVHD) and improving immune engraftment following hematopoietic stem cell transplantation (HSCT). The project, conducted in collaboration with researchers at the...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $810,875 to The Trustees of the University of Pennsylvania to conduct pre-clinical research on developing chimeric antigen receptor (CAR) T cell therapies as a curative treatment for immune thrombotic thrombocytopenic purpura (iTTP), a life-threatening autoimmune disorder. The researchers are exploring two novel CAR T cell platforms that...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $231,131 to Duquesne University to develop and evaluate an injectable 3D-clustered human fibroblastic reticular cell (FRC) formulation for expanding regulatory T cells (Tregs). The goal is to leverage FRC-mediated tolerance to prevent allograft rejection in transplant recipients, an alternative to the current...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,001,029 to Immunova Therapeutics LLC for the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award period runs from September 20, 2024 to August 31, 2026. The key products and services to be delivered under this grant include: Generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4...

This $650,450 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel TCR-engineered CD4+ T cell therapy for the treatment of lung cancer. The funded research project, led by the University of Southern California, aims to: Determine the mechanisms by which the proprietary "MIIC4 TCRM50A-STEM2 T cells" (or IMT-423) eliminate lung cancer cells. Produce GMP-grade master cell bank and viral...

This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,108,154 to The Regents of the University of California, San Francisco (UCSF) to develop a stem cell-based multi-cellular platform that integrates diverse immune cells with stem cell-derived islets. The goal is to create an improved preclinical research model to accelerate the...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,074,434.37 Project Grant to the Massachusetts General Hospital under the Allergy and Infectious Diseases Research program (CFDA 93.855) on March 17, 2021 with a completion date of July 12, 2021. The grant funding supports research to develop protocols to induce tolerance in non-human primate heart allograft recipients without chronic immunosuppression. The awardee will test approaches to either...